Business Description
Akebia Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00972D1054
Total Employee Number:
194Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.19 | |||||
Equity-to-Asset | 0.08 | |||||
Debt-to-Equity | 1.86 | |||||
Debt-to-EBITDA | 14.09 | |||||
Interest Coverage | 0.25 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -5.1 | |||||
Beneish M-Score | -3.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.9 | |||||
3-Year EPS without NRI Growth Rate | 71.4 | |||||
3-Year Book Growth Rate | 63.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -71.04 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -6.34 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.05 | |||||
9-Day RSI | 66.29 | |||||
14-Day RSI | 59.25 | |||||
3-1 Month Momentum % | -24.97 | |||||
6-1 Month Momentum % | -35.24 | |||||
12-1 Month Momentum % | -71.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.4 | |||||
Quick Ratio | 1.33 | |||||
Cash Ratio | 0.94 | |||||
Days Inventory | 138.45 | |||||
Days Sales Outstanding | 97.42 | |||||
Days Payable | 105.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13 | |||||
Shareholder Yield % | -1.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.01 | |||||
Operating Margin % | 2.28 | |||||
Net Margin % | -8.83 | |||||
EBITDA Margin % | 1.56 | |||||
FCF Margin % | 22.33 | |||||
OCF Margin % | 25.81 | |||||
ROE % | -66 | |||||
ROA % | -5.83 | |||||
ROIC % | 2.73 | |||||
3-Year ROIIC % | -337 | |||||
ROC (Joel Greenblatt) % | 32.46 | |||||
ROCE % | 1.08 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 14.91 | |||||
PS Ratio | 1.32 | |||||
PB Ratio | 11.18 | |||||
Price-to-Free-Cash-Flow | 5.94 | |||||
Price-to-Operating-Cash-Flow | 5.14 | |||||
EV-to-EBIT | 83.02 | |||||
EV-to-EBITDA | 53.61 | |||||
EV-to-Revenue | 0.84 | |||||
EV-to-Forward-Revenue | 0.89 | |||||
EV-to-FCF | 3.72 | |||||
Price-to-GF-Value | 0.87 | |||||
Earnings Yield (Greenblatt) % | 1.2 | |||||
FCF Yield % | 17.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akebia Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 199.757 | ||
| EPS (TTM) (€) | -0.069 | ||
| Beta | 1.6591 | ||
| 3-Year Sharpe Ratio | 0.27 | ||
| 3-Year Sortino Ratio | 0.48 | ||
| Volatility % | 48.07 | ||
| 14-Day RSI | 59.25 | ||
| 14-Day ATR (€) | 0.059173 | ||
| 20-Day SMA (€) | 0.85484 | ||
| 12-1 Month Momentum % | -71.81 | ||
| 52-Week Range (€) | 0.7222 - 3.392 | ||
| Shares Outstanding (Mil) | 268.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akebia Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akebia Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 08:00 | In 135 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 134 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:00 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 39 days | ||
| General meeting for 2026 | 2026-06-17 10:00 | 0.84 (+6.60%) | ||
| Guidance call for 2026 | 2026-06-04 07:35 | 0.83 (+4.62%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 1.25 (+2.37%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.25 (+2.37%) | ||
| Akebia Therapeutics Virtual R&D Day | 2026-04-02 10:00 | 1.21 (+3.24%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 08:00 | 1.08 (+7.68%) |
Show
Entries
Akebia Therapeutics Inc Frequently Asked Questions
What is Akebia Therapeutics Inc(STU:AX9)'s stock price today?
The current price of STU:AX9 is €0.98. The 52 week high of STU:AX9 is €3.39 and 52 week low is €0.72.
When is next earnings date of Akebia Therapeutics Inc(STU:AX9)?
The next earnings date of Akebia Therapeutics Inc(STU:AX9) is 2026-08-07 Est..
Does Akebia Therapeutics Inc(STU:AX9) pay dividends? If so, how much?
Akebia Therapeutics Inc(STU:AX9) does not pay dividend.
Press Release
Articles on Akebia Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers